Ubs Group Ag Connect Biopharma Holdings LTD Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.82 - $1.32 $7,214 - $11,613	-8,798 Reduced 48.52%	9,336 $9,000
Q4 2022 Feb 08, 2023	BUY	$0.64 - $1.31 $11,288 - $23,105	17,638 Added 3556.05%	18,134 $15,000
Q3 2022 Nov 10, 2022	SELL	$0.8 - $1.65 $83,751 - $172,736	-104,689 Reduced 99.53%	496 $1,000
Q2 2022 Aug 10, 2022	BUY	$0.56 - $3.25 $57,861 - $335,803	103,324 Added 5552.07%	105,185 $91,000
Q1 2022 May 16, 2022	BUY	$2.46 - $5.92 $2,656 - $6,393	1,080 Added 138.28%	1,861 $6,000
Q4 2021 Feb 14, 2022	BUY	$4.26 - $23.33 $1,473 - $8,072	346 Added 79.54%	781 $4,000
Q3 2021 Nov 15, 2021	BUY	$18.12 - $28.5 $7,882 - $12,397	435 New	435 $11,000

3.05M

Ticker CNTB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,015,800
Market Cap $55M
Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for t...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.